M-032

Generic Name: M-032

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: -

Unique Ingredient Identifier: -

Associated Conditions: -

Associated Therapies: -

Clinical Trials

pmc.ncbi.nlm.nih.gov

·

a year ago

The next generation of herpes simplex virus-based oncolytic immunotherapy

The article reviews the evolution of oncolytic immunotherapy (OI) since the FDA approved talimogene laherparepvec for melanoma in 2015. It discusses the development of next-generation herpes simplex virus-based OIs, focusing on genetic modifications for safety, tumor-selective replication, and immune stimulation. The review also covers clinical evidence supporting OIs in overcoming resistance to immune checkpoint blockade and explores combination therapies to enhance OI efficacy.

Related Clinical Trials:

TVEC and Preop Radiation for Sarcoma (8 ml Dose)

Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

TVEC and Preop Radiation for Sarcoma (4 ml Dose)

Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611

Study of TVEC in Patients With Cutaneous Squamous Cell Cancer

Phase II Multicenter Study of Talimogene Laherparepvec in Classic or Endemic Kaposi Sarcoma

Neoadjuvant T-VEC in High Risk Early Melanoma

A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma

Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (Stage IIIB/C/D-IV M1a) Melanoma With Injectable Disease

Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma

Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma

Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

Neoadjuvant Combination Immunotherapy for Stage III Melanoma

Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).

A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors

OH2 Oncolytic Viral Therapy in Non-Muscle-Invasive Bladder Cancer

OH2 Oncolytic Viral Therapy in Central Nervous System Tumors

OH2 Oncolytic Viral Therapy in Pancreatic Cancer

OH2 Injection in Combination With HX008 for Melanoma.

OH2 Oncolytic Viral Therapy in Solid Tumors

OH2 Injection in Solid Tumors

OH2 Oncolytic Viral Therapy in Advanced Bladder Cancer

First-line Maintenance of OH2 Injection for Advanced Colorectal Cancer

A Phase 1B/2 Study of RP1 in Solid Organ Transplant Patients With Advanced Cutaneous Malignancies

Study of RP1 Monotherapy and RP1 in Combination With Nivolumab

Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer

RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC

RP3 in Combination With 1L or 2L Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC

Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN

A Study of T3011 Administered Via Intravenously in Patients With Advanced Solid Tumors.

A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors

Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors

A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma

HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma

Clinical Study of VG161 in Combination With Nivolumab in Subjects With Advanced Pancreatic Cancer

An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Study of Pembrolizumab and M032 (NSC 733972)

A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma

Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients with Unresectable Pancreatic Cancer.

Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors

Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors

Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours

MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Safety and Efficacy of Repeated Infusion of CELYVIR in Children and Adults With Metastatic and Refractory Tumors.

MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma

Phase I/II Study of AloCelyvir in Patients With Metastatic Uveal Melanoma

A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX)

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy